All In Biotech

Drug Trial Radar · NCT07226752

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

72

Actual

Start

Oct 8, 2022

Primary completion

Oct 13, 2025

Study completion Jun 14, 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Nov 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Chinese sub-study trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin \[R-GemOx\], or bendamustine + rituximab \[BR\]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT). Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously. Trial details include: The trial duration will be up to 5 years after last participant is randomized. All trial participants have a 21-day screening period, a treatment period, and a follow-up period that continues until death. The estimated trial duration for an individual participant depends upon the treatment arm assigned: Participants who receive epcoritamab will have 28-day treatment cycles. Epcoritamab will be given once weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse events. Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either: R-GemOx: On Day 1 (or Day 1 \& Day 2), and Day 15 (or Day 15 \& Day 16) every 28 days, for up to 4 months; or BR: On Day 1 and Day 2 every 3 weeks for up to 4.5 months.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • EpcoritamabBiological

    Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.

  • Investigator's Choice ChemotherapyDrug

    Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 3 years

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Hebei University

    Baoding, China

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • The Second Hospital of Dalian Medical University

    Dalian, China

  • Guangdong Provincial Peoples Hospital

    Guandong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Guangxi, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Hubei Cancer Hospital

    Hubei, China

  • Hunan Cancer Hospital

    Hunan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • Qingdao Central Hospital

    Qingdao, China

  • Shanxi Provincial Cancer Hospital

    Shanxi, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Shenzhen Peoples Hospital

    Shenzhen, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

  • EC of Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Yantai Yuhuangding Hospital

    Yantai, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Zhenjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.